SANGAMO THERAPEUTICS INC (SGMO)
US8006771062 - Common Stock
Overall SGMO gets a fundamental rating of 2 out of 10. We evaluated SGMO against 565 industry peers in the Biotechnology industry. While SGMO seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, SGMO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
SGMO had negative earnings in the past year.
In the past year SGMO has reported a negative cash flow from operations.
In the past 5 years SGMO always reported negative net income.
In the past 5 years SGMO reported 4 times negative operating cash flow.
1.2 Ratios
SGMO's Return On Assets of -165.31% is on the low side compared to the rest of the industry. SGMO is outperformed by 87.52% of its industry peers.
With a Return On Equity value of -470.00%, SGMO is not doing good in the industry: 79.68% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -165.31% | ||
| ROE | -470% | ||
| ROIC | N/A |
ROA(3y)-71.61%
ROA(5y)-48.53%
ROE(3y)-141.25%
ROE(5y)-94.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SGMO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SGMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
SGMO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SGMO has more shares outstanding
There is no outstanding debt for SGMO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
SGMO has an Altman-Z score of -19.62. This is a bad value and indicates that SGMO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SGMO (-19.62) is worse than 85.03% of its industry peers.
There is no outstanding debt for SGMO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -19.62 |
ROIC/WACCN/A
WACC10.43%
2.3 Liquidity
A Current Ratio of 1.35 indicates that SGMO should not have too much problems paying its short term obligations.
SGMO has a Current ratio of 1.35. This is amonst the worse of the industry: SGMO underperforms 83.07% of its industry peers.
SGMO has a Quick Ratio of 1.35. This is a normal value and indicates that SGMO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.35, SGMO is doing worse than 82.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 48.28% over the past year.
The Revenue for SGMO has decreased by -73.80% in the past year. This is quite bad
SGMO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.84% yearly.
EPS 1Y (TTM)48.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.78%
Revenue 1Y (TTM)-73.8%
Revenue growth 3Y14.24%
Revenue growth 5Y15.84%
Sales Q2Q%425.75%
3.2 Future
The Earnings Per Share is expected to grow by 18.70% on average over the next years. This is quite good.
The Revenue is expected to grow by 12.62% on average over the next years. This is quite good.
EPS Next Y66.52%
EPS Next 2Y35.98%
EPS Next 3Y23.79%
EPS Next 5Y18.7%
Revenue Next Year-73.74%
Revenue Next 2Y-32.83%
Revenue Next 3Y-16.89%
Revenue Next 5Y12.62%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SGMO. In the last year negative earnings were reported.
Also next year SGMO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SGMO's earnings are expected to grow with 23.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.98%
EPS Next 3Y23.79%
5. Dividend
5.1 Amount
No dividends for SGMO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SANGAMO THERAPEUTICS INC
NASDAQ:SGMO (11/22/2024, 8:04:36 PM)
After market: 1.88 0 (0%)1.88
-0.08 (-4.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap392.26M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -165.31% | ||
| ROE | -470% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)48.28%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y66.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-73.8%
Revenue growth 3Y14.24%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y